Prognosis

xSuite Business Solutions Cube Receives Renewed SAP Certifications

Retrieved on: 
Friday, February 4, 2022
Software, Technology, Data Management, Cloud, ECC, AP, CEO, Automation, Efficiency, SAP NetWeaver, SAP S/4HANA, Certification, XSuit, Prognosis, SAP, Solution, Software, SAP ERP

The current release 5.2. of the SAP-integrated workflow suite "xSuite Business Solutions Cube" has been successfully recertified by SAP, for SAP NetWeaver and the new versions of SAP S/4HANA and S/4HANA Cloud (released October 2021).

Key Points: 
  • The current release 5.2. of the SAP-integrated workflow suite "xSuite Business Solutions Cube" has been successfully recertified by SAP, for SAP NetWeaver and the new versions of SAP S/4HANA and S/4HANA Cloud (released October 2021).
  • xSuite Cube solutions can run in all environments and are certified for SAP NetWeaver (ECC systems), SAP S/4HANA and SAP S/4HANA Cloud.
  • The "Integration with SAP S/4HANA" certification has been expanded to include the Private Edition and "RISE with SAP."
  • According to Matthias Lemenkhler, CEO of xSuite Group, "The automation of document-based business processes with SAP is our core business, which is why we regularly have our software certified in its full spectrum.

Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 and MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells

Retrieved on: 
Thursday, February 3, 2022
Diagnosis, Private Securities Litigation Reform Act, DNA, Temozolomide, TMZ, Patient, Therapy, B cell, Cell, SAN, Central nervous system, Cancer, National, National Cancer Institute, SEC, Bladder cancer, Radiation, Patent, Technology, Glioblastoma, Research, COVID-19, GBM, Marketing, Annual report, NSCLC, Company, Ovary, Neck, Drug resistance, Medulloblastoma, MGMT, Head, NCI, Prognosis, DNA repair, CMBC, Sumathi Best Television Current Reporting Award, Nasdaq, Medical imaging, Pharmaceutical industry

The patent allows for claims recognizing the unique anti-neoplastic activity of VAL-083 on malignant brain tumor cells, in particular those cells that express the DNA repair enzyme MGMT.

Key Points: 
  • The patent allows for claims recognizing the unique anti-neoplastic activity of VAL-083 on malignant brain tumor cells, in particular those cells that express the DNA repair enzyme MGMT.
  • Moreover, MGMT is a biomarker used in the diagnosis of a patient's brain tumor and helps clinicians to understand the patient's prognosis.
  • "The effect of VAL-083 on brain tumor stem cells represents a unique advance," Dennis Brown, Ph.D., Kintara's Chief Scientific Officer said.
  • "These undifferentiated stem cells are resistant to radiation and chemotherapy and are thought to represent the source of most brain tumor recurrences.

Millions of Siemens Healthineers CLINITEST Rapid COVID-19 Antigen Self-Test Now Available in the U.S.

Retrieved on: 
Thursday, February 3, 2022
Medical Supplies, FDA, Health, Infectious Diseases, General Health, Biotechnology, Diagnosis, Patient, Infection, EBIT, Hematology, Federal Food, Drug, and Cosmetic Act, Omicron, Delta, Inflammation, COVID, American Federation of Teachers, COVID-19, Nursing, Partnership, Siemens Healthineers, Student, Prognosis, Power-on self-test, Severe acute respiratory syndrome coronavirus 2, Coagulation, Virus, Federation, FDA, Protein, Multimedia, Emergency Use Authorization, Solution, Vaccine, Pharmaceutical industry, Medical imaging

Siemens Healthineers announced today the CLINITEST Rapid COVID-19 Antigen Self-Test1,2 is now available in the U.S. to self-test for the SARS-CoV-2 virus.

Key Points: 
  • Siemens Healthineers announced today the CLINITEST Rapid COVID-19 Antigen Self-Test1,2 is now available in the U.S. to self-test for the SARS-CoV-2 virus.
  • View the full release here: https://www.businesswire.com/news/home/20220201006000/en/
    Siemens Healthineers announced today the CLINITEST Rapid COVID-19 Antigen Self-Test is now available in the U.S. to self-test for the SARS-CoV-2 virus.
  • (Photo: Scott Dalton/AP Images for Siemens Healthineers)
    "Siemens Healthineers is bringing millions of rapid COVID-19 antigen tests to the United States to make them available to the American people at a time when the tests are desperately needed," said Jennifer Zinn, Executive Vice President and Head of Diagnostics, North America, Siemens Healthineers.
  • Siemens Healthineers committed to making tens of millions of tests available for the federal government over the next two months.

Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Retrieved on: 
Wednesday, February 2, 2022
Private Securities Litigation Reform Act, Patient, SAN, Lipotriches exagens, Rheumatoid arthritis, SEC, Digital health, Rheumatology, Technology, COVID-19, Cell-bound complement activation products, Lupus, U.S. Securities and Exchange Commission, Annual report, GLOBE, Prognosis, Movement, Therapy, Security (finance), Conference, Pharmaceutical industry

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 15-17, 2022.

Key Points: 
  • SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 15-17, 2022.
  • Management will also be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG.
  • Exagen cautions you that statements in this press release regarding matters that are not historical facts are forward-looking statements.
  • The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved.

Biomarker Discovery from Gene Expression: Challenges and Solutions for Success, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, February 2, 2022
Icahn Institute for Data Science and Genomic Technology, Diagnosis, Prognosis, VP, Food, Industry, Gene, Gene expression, Biomarker discovery, Success, Solution, Clinical trial, Medical device

However, this potential has yet to be fully realized despite the exponential increase in genomic data during this period.

Key Points: 
  • However, this potential has yet to be fully realized despite the exponential increase in genomic data during this period.
  • A strategic approach for biomarker discovery aligned with the development and validation path of the therapeutic is essential.
  • Almac Diagnostics Services has substantial expertise in biomarker discovery from gene expression, taking them beyond the proof-of-concept phase to analytically validate and deliver prospectively for clinical trial stratification.
  • For more information, or to register for this event, visit Biomarker Discovery from Gene Expression: Challenges and Solutions for Success.

NPHI Roundtable Celebrates National Heart Health Month: "In-Home Cardiac Care is All Heart"

Retrieved on: 
Tuesday, February 1, 2022
EST, Risk, Patient, Parent, Health care, Hospital, NPHI, Gaps, MD, Face, Program, ACC, Palliative care, Perception, Pain management, Adoption, Capital, American Heart, Research, COVID-19, Population, Death, American Heart Association, ICU, Prevalence, Journal, Kaiser Permanente, Journal of the American Heart Association, Heart failure, Ageing, Cardiovascular disease, Heart, National Partnership, Life, Prognosis, Veterans' affairs, Communication, Quality of life, Minneapolis Veterans Affairs Health Care System, Caregiver, Hospice, Medicine, Management, Medical device, Residential care

Since then, top performing NPHI programs have seen nearly 30% increases in cardiac patient admissions and improved clinical outcomes, even in the face of COVID-19 restrictions.

Key Points: 
  • Since then, top performing NPHI programs have seen nearly 30% increases in cardiac patient admissions and improved clinical outcomes, even in the face of COVID-19 restrictions.
  • "Serious cardiac illness can be daunting for patients, families, and caregivers, which is why our programs never turn anyone away, regardless of ability to pay."
  • "We're so proud of the work our members have done to support this population," added Carole Fisher, President, NPHI.
  • Compared to those without hospice and palliative care, patients in said member programs were:
    Palliative care has already transformed the care experience for many families.

Comera Life Sciences to Become Publicly Traded via Business Combination with OTR Acquisition Corp.

Retrieved on: 
Monday, January 31, 2022
Research, Biotechnology, Other Health, Managed Care, Health, Pharmaceutical, Other Science, Science, Oncology, Growth, Risk, Biotechnology, Form, Market, Technology, Adoption, Brickell Avenue, Nasdaq, Compliance, Acquisition, Multimedia, U.S. Securities and Exchange Commission, Prospectus, 100,000, Quality of life, Research, Director, Leadership, View, Failure, SPAC, Person, Prognosis, Industry, EST, Safety, Forward-looking statement, Patient, OTR, SEC, Medicine, Freedom, LLP, Reading, Suite, Saudi Research and Marketing Group, Therapy, Pharmaceutical industry, Management, Security (finance), Risk management, Ownership, Holding company, Comera Life Sciences, OTR Acquisition Corp., COMERA LIFE SCIENCES, OTR ACQUISITION CORP.

Comera Life Sciences, Inc. (Comera or the Company), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (Nasdaq: OTRAU, OTRA and OTRAW) (collectively referred herein as OTR), a publicly traded special purpose acquisition company (SPAC), today announced they have entered into a business combination agreement.

Key Points: 
  • Comera Life Sciences, Inc. (Comera or the Company), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (Nasdaq: OTRAU, OTRA and OTRAW) (collectively referred herein as OTR), a publicly traded special purpose acquisition company (SPAC), today announced they have entered into a business combination agreement.
  • Maxim Group LLC served as sole financial and capital markets advisor to Comera in connection with the business combination agreement.
  • Comera and OTR will hold an investor call on Friday, Feb. 4 at 8:30 a.m. EST to discuss the business combination.
  • Neither Holdco, Comera nor OTR gives any assurance that either Comera or OTR will achieve its expectations.

Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests

Retrieved on: 
Saturday, January 29, 2022
Diagnosis, CEP, Broad, CEO, Safety, Private Securities Litigation Reform Act, Risk, CMS, Health, Policy, Physician, Goal, Technology, Centers for Medicare & Medicaid Services, Securities Act of 1933, Center, Medicare, COVID-19, Cancer, Pharma, Pancreatic cancer, U.S. Securities and Exchange Commission, Franciscan Ceramics, Company, Lung cancer, GLOBE, Esophageal cancer, EBITDA, Pancreatic cyst, Prognosis, Drug development, Securities Exchange Act of 1934, Comerica, Security (finance), Thyroid cancer, Terminology, Sumathi Best Television Current Reporting Award, OTCQX, Pharmaceutical industry, Risk management

The CMS change does not in any way impact the efficacy of the diagnostic information provided to clinicians.

Key Points: 
  • The CMS change does not in any way impact the efficacy of the diagnostic information provided to clinicians.
  • We will continue to evaluate the impact of the change in the CMS policy and potential changes on the Companys operations and will keep our stockholders informed.
  • Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
  • Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements.

I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs

Retrieved on: 
Friday, January 28, 2022
IND, Private Securities Litigation Reform Act, Safety, Patient, Progression-free survival, Intellectual property, Immune system, ADCC, Food, Lymphatic system, NMPA, Lenalidomide, WeChat, Cancer, EMA, Twitter, MM, National Medical Products Administration, Technology, ADCP, COVID-19, Degenerative disease, Partnership, Disease, CDC, Antigen, Annual report, GMP, Neoplasm, Company, Form 20-F, Multiple myeloma, Ageing, European Medicines Agency, Incidence, CD38, Prognosis, Lishui, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, FDA, LinkedIn, Risk, U.S. Securities and Exchange Commission, Pharmaceutical industry, Fine chemical, MorphoSys

This strategic partnership will accelerate I-Mab's commercialization strategy with an execution plan and timeline to commercialize its innovative assets, including felzartamab (TJ202/MOR202),and meet unmet medical needs for patients in China.

Key Points: 
  • This strategic partnership will accelerate I-Mab's commercialization strategy with an execution plan and timeline to commercialize its innovative assets, including felzartamab (TJ202/MOR202),and meet unmet medical needs for patients in China.
  • "This brings us one step closer to our new commercial model that integrates manufacturing, distribution and sales."
  • The first planned I-Mab's innovative assets to be locally manufactured at I-Mab Hangzhou is felzartamab (TJ202/MOR202), a differentiated antibodydrug.
  • I-Mab owns the exclusive rights for development and commercialization of TJ202/MOR202 in mainland China, Taiwan, Hong Kong and Macao.

Genetic ancestry provides important context for understanding global diversity in childhood leukemia

Retrieved on: 
Thursday, January 27, 2022
St. Jude Children's Research Hospital, Biology, UCSF Benioff Children's Hospital, Genetic variation, ALSAC, JAMA Oncology, Cancer, CRLF2, Patient, Philadelphia, DUX4, University, KK Women's and Children's Hospital, National, Andijan State Medical Institute, University of California, National Cancer Institute, Child, T-ALL, Acute lymphoblastic leukemia, Social media, Department, Leukemia, Research, ALL, Multimedia, NCI-designated Cancer Center, Survival, Children's Hospital of Philadelphia, Prognosis, Risk, Incidence, Yang, NUDT15, Toxicity, Awareness, Hospital, University Malaya Medical Centre, Medicine, Vaccine, Pharmacy, Native, Jude the Apostle

The scientists assembled an international cohort to determine how genetic ancestry affects leukemia biology and outcomes for modern therapy.

Key Points: 
  • The scientists assembled an international cohort to determine how genetic ancestry affects leukemia biology and outcomes for modern therapy.
  • Racial disparities exist in both the incidence and treatment outcomes for childhood ALL, and there is limited data on the genetic basis for such disparities.
  • The researchers used a genomic technique called RNA-sequencing to comprehensively characterize ALL molecular subtype and genetic ancestry of each child.
  • These NUDT15 variants are rarely found in children with European ancestry, highlighting how important findings can be missed if studies do not include diversity in genetic ancestry.